Intertek
Total Quality Assurance Provider to Industries Worldwide

In the current scenario, a growing focus on introducing different drug types has spurred a demand for creating effective analytical testing of biosimilars and biologics that can contribute to the market expansion. That said, reputed biopharmaceutical companies are in need to outsource analytical testing solutions and save costs in R&D expenditure. However, there is a lack of professionals who adopt an efficient quality by design approach for drug formulation that adheres to the ever-dynamic regulations. For more than 130 years, Intertek has helped companies ensure the quality and safety of products, processes and systems. The firm is an industry leader and goes beyond testing, inspecting and certifying products through a worldwide network of industry-leading technical expertise and state-of-the-art facilities. “Our company provides innovative and bespoke Assurance, Testing, Inspection and Certification services to customers,”- André Lacroix, Chief Executive Officer.

Intertek uses a unique systemic approach to supporting its customers’ Quality Assurance efforts in each of the areas of their operations, including R&D, raw materials sourcing, components suppliers, manufacturing, transportation, distribution and consumer management. The company holds extensive global accreditations, recognitions, and agreements with its industry-winning processes and customer-centric culture. Experts at Intertek help companies achieve a “well-characterized” protein drug substance or drug product in protein analysis with the ICH Q6B Guidance, including protein structure analysis, physiochemical property determination, potency assays and product-related and process-related impurity testing. During preclinical and clinical development, the firm designs and manages strategic work programs with the aim to supply results as quickly and efficiently as possible.

As a world-leading provider of immunochemistry services and biomarker expertise for bioanalytical studies, Intertek also applies its analytical expertise for identity confirmation, comparability, stability testing and batch release testing. To ensure a safe and efficacious biologic product, experts at Interlek are adept at developing and validating assays for bioanalytical pharmacokinetic (PK), toxicokinetic (TK), immunogenicity, and biomarker studies from early discovery through to late-stage clinical studies. In addition, to support its clients to develop highly complex biopharmaceutical products, the firm provides characterization and testing expertise for antibodies, bispecifics, oligonucleotides, cell and gene therapies, viral species and vaccines.

Since its inception, Intertek has always been a pioneer by anticipating the needs of its clients with bold innovations. True to the innovative spirit of its founder, Thomas Edison, the firm aims to redefine the industry with an end-to-end ‘Total Quality Assurance’ value proposition going beyond services to offer clients a ‘Peace of Mind.’ As an industry leader with more than 43,800 employees in 1,000 locations in over 100 countries, Interlek’s knowledge and expertise in overcoming regulatory, market, and supply chain hurdles is unrivalled. One of Intertek’s primary business objectives is to ensure that a company’s practices adhere to local, national and international regulations. The firm utilizes risk management strategies and internal controls, which are embedded throughout its operations to assure the accuracy and validity of reports and certificates provided to customers. “Whether your business is local or global, Intertek can help ensure your products meet quality, health, environmental, safety, and social accountability standards for virtually any market around the world,”- André Lacroix, Chief Executive Officer.